(Not giving up) the marathon race of Met targeting therapy: Are we there yet?

Research output: Contribution to journalArticle

Abstract

Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

Original languageEnglish (US)
Pages (from-to)2375-2378
Number of pages4
JournalClinical Cancer Research
Volume25
Issue number8
DOIs
StatePublished - Apr 15 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '(Not giving up) the marathon race of Met targeting therapy: Are we there yet?'. Together they form a unique fingerprint.

  • Cite this